Brief: Merit Medical Provides Update On US Reimbursement And Commercial Strategies For Wrapsody Cell-Impermeable Endoprosthesis
13/11/2025 21:20
Nov 13 (Reuters) - Merit Medical Systems Inc MMSI.O: MERIT MEDICAL PROVIDES UPDATE ON U.S. REIMBURSEMENT AND COMMERCIAL STRATEGIES FOR WRAPSODY® CELL-IMPERMEABLE ENDOPROSTHESIS MERIT MEDICAL SYSTEMS INC - CMS DEFERS WRAPSODY CIE APPLICATION TO 2027 OUTPATIENT PROSPECTIVE PAYMENT SYSTEM RULE MERIT MEDICAL SYSTEMS INC - FORECASTS $2 MILLION-$4 MILLION U.S. REVENUE FROM WRAPSODY CIE IN 2025 Source text: ID:nGNX6QJv0f Further company coverage: MMSI.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Merit Medical Systems
See all newsMerit Medical Systems Inc reports results for the quarter ended March 31 - Earnings Summary
Merit Medical Q2 adjusted EPS beats estimates, raises 2026 outlook
Brief: Merit Medical Systems Q2 Adjusted EPS USD 1.19 Vs. IBES Estimate USD 0.96
Brief: Merit Medical Shareholders Elect Scott R. Ward To Board Of Directors
Merit Medical Q1 adjusted EPS rises on therapeutic, foundational growth